Jugel, W.; Aigner, A.; Michen, S.; Hagstotz, A.; Ewe, A.; Appelhans, D.; Schackert, G.; Temme, A.; Tietze, S.
Targeted RNAi of BIRC5/Survivin Using Antibody-Conjugated Poly(Propylene Imine)-Based Polyplexes Inhibits Growth of PSCA-Positive Tumors. Pharmaceutics 2021, 13, 676.
https://doi.org/10.3390/pharmaceutics13050676
AMA Style
Jugel W, Aigner A, Michen S, Hagstotz A, Ewe A, Appelhans D, Schackert G, Temme A, Tietze S.
Targeted RNAi of BIRC5/Survivin Using Antibody-Conjugated Poly(Propylene Imine)-Based Polyplexes Inhibits Growth of PSCA-Positive Tumors. Pharmaceutics. 2021; 13(5):676.
https://doi.org/10.3390/pharmaceutics13050676
Chicago/Turabian Style
Jugel, Willi, Achim Aigner, Susanne Michen, Alexander Hagstotz, Alexander Ewe, Dietmar Appelhans, Gabriele Schackert, Achim Temme, and Stefanie Tietze.
2021. "Targeted RNAi of BIRC5/Survivin Using Antibody-Conjugated Poly(Propylene Imine)-Based Polyplexes Inhibits Growth of PSCA-Positive Tumors" Pharmaceutics 13, no. 5: 676.
https://doi.org/10.3390/pharmaceutics13050676
APA Style
Jugel, W., Aigner, A., Michen, S., Hagstotz, A., Ewe, A., Appelhans, D., Schackert, G., Temme, A., & Tietze, S.
(2021). Targeted RNAi of BIRC5/Survivin Using Antibody-Conjugated Poly(Propylene Imine)-Based Polyplexes Inhibits Growth of PSCA-Positive Tumors. Pharmaceutics, 13(5), 676.
https://doi.org/10.3390/pharmaceutics13050676
